Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some user statements align with the label (Centany contains mupirocin; mupirocin is for topical impetigo; label-supported dosing concept). However, multiple claims about treating other bacterial skin infections/wounds/minor cuts and broad-spectrum Gram-positive/Gram-negative activity are not supported by the provided prescribing information excerpts and include unsupported mechanistic statements.
Category Scores
Accurate Statements
Centany is an antibiotic ointment containing the active ingredient mupirocin.
Supported by the drug description in the label excerpts provided (Centany (mupirocin ointment), 2%).
Centany is a branded ointment that contains mupirocin.
Supported by label naming (Centany (mupirocin ointment), 2%).
Mupirocin is the generic name of the active ingredient.
Supported by the label naming (Centany (mupirocin ointment), 2%).
Mupirocin is effective against both Gram-positive and Gram-negative bacteria.
No label excerpt provided that supports spectrum/Gram coverage.
Unsupported Statements
Centany is used topically to treat bacterial infections of the skin.
Label excerpt provided indicates topical treatment of impetigo only; no broader 'bacterial infections of the skin' claim is supported.
Centany is used topically to treat infected wounds.
No label excerpt provided supports indications for infected wounds.
Centany is used topically to treat minor cuts.
No label excerpt provided supports indications for minor cuts.
Mupirocin is a broad-spectrum antibiotic.
No label excerpt provided supports broad-spectrum activity.
Mupirocin is effective against both Gram-positive and Gram-negative bacteria.
No label excerpt provided supports Gram-positive/Gram-negative spectrum.
Mupirocin works by inhibiting the growth of bacteria.
No label excerpt provided describes the mechanism of action.
Mupirocin works by preventing the spread of infection.
No label excerpt provided describes such a mechanism.
In summary, Centany and mupirocin are essentially the same thing.
Label excerpts distinguish the product name (Centany) from the active ingredient (mupirocin); no basis is provided to state they are 'essentially the same thing.'
Centany is a brand name owned by GlaxoSmithKline.
No label excerpt provided supports the ownership/company claim.
The branded form of mupirocin may contain additional ingredients or formulations not present in the generic version.
No label excerpt provided supports any comparison between brand and generic formulations.
Contradictions
Low
AI Statement
Mupirocin works by preventing the spread of infection.
Label Reference
No contradiction can be established from the provided excerpts; this is not directly supported but also not directly contradicted.
Important Omissions
Specific label-supported indication detail (impetigo due to Staphylococcus aureus and Streptococcus pyogenes) and re-evaluation timeframe (3 to 5 days) were not clearly included within the provided AI statements list.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Overbroad indication claims (e.g., infected wounds, minor cuts, general skin bacterial infections) are not supported by the supplied label excerpts and could lead to inappropriate use relative to on-label indications.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
Yes |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple non-label-supported indication and mechanistic/broad-spectrum claims were made beyond the provided label excerpts (impetigo due to specific organisms).
Suggested Improvement
Restrict claims to on-label indication (topical impetigo due to Staphylococcus aureus and Streptococcus pyogenes) and on-label administration guidance from the provided excerpts; remove or qualify unsupported mechanism/spectrum/ownership and avoid implying use for infected wounds or minor cuts.